Vacaville Product Operations Genentech's facility in Vacaville, California, is one of the world's largest biotechnology manufacturing plants for the large-scale production of pharmaceutical proteins from mammalian cells. The facility opened in 1998 and was licensed by the U.S. Food and Drug Administration (FDA) in May 2000. As of July 30, 2008, Genentech Vacaville Product Operations has approximately 830 regular full-time employees in the areas of manufacturing, quality and administration.

Products Manufactured in Vacaville Genentech's Vacaville Product Operations is licensed by the FDA to manufacture four FDA-approved products:

• Avastin® (bevacizumab) is the first FDA-approved therapy designed to inhibit angiogenesis, the process by which new blood vessels develop and carry vital nutrients to a tumor. The FDA approved Avastin in February 2004. Avastin is approved for use for use in combination with intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum. In October 2006, the FDA also approved Avastin in combination with carboplatin and paclitaxel for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC)
• Herceptin® (Trastuzumab) is indicated, in combination with paclitaxel and as a single agent in patients who have received on or more chemotherapy regimens, for the treatment of HER2-positive metastatic breast cancer; as part of a treatment regimen containing doxorubicin, cyclophosphamide and paclitaxel, for the adjuvant treatment of patients with HER2-positive, node-positive breast cancer; and as a single agent, for the adjuvant treatment of HER2-overexpressing node-negative (ER/PR-negative or with one high-risk feature) or node-positive breast cancer, following multi-modality anthracycline-based therapy. Herceptin, approved by the FDA in 1998, is the first humanized antibody approved for the treatment of HER2 positive metastatic breast cancer. Herceptin is designed to target and block the function of HER2 protein overexpression.
• Rituxan® (Rituximab) is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; for previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens; for previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy; for the treatment of non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent, after first-line CVP chemotherapy; and for use in combination with methotrexate (MTX) for reducing signs and symptoms and to slow the progression of structural damage in adult patients with moderately- to severely-active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
• Xolair® (Omalizumab) for Subcutaneous Use is indicated for the treatment of moderate-to-severe persistent asthma in adults and adolescents. Approved by the FDA in 2003, Xolair is the first humanized therapeutic antibody for the treatment of asthma and the first approved therapy designed to target the antibody IgE, a key underlying cause of the symptoms of allergy related asthma.

Current Facility Genentech's Vacaville Product Operations is located on a 100-acre site, about 50 miles northeast of San Francisco and 30 miles southwest of Sacramento along Interstate 80. The plant is located 60 miles from Genentech's corporate headquarters in South San Francisco.

Genentech's existing buildings in Vacaville cover approximately 33 acres and comprise more than 427,000 square feet of space devoted to manufacturing, maintenance, laboratories, office space and warehousing.

Vacaville Product Operations currently houses twelve 12,000-liter fermenters, in which mass cultures grow and products develop.

Expansion On April 1, 2004, Genentech announced its decision to expand its Vacaville facility. The expansion includes both manufacturing and administrative buildings.

In addition to the existing capacity, the new manufacturing facility will be configured with eight, 25,000-liter fermentation tanks and will add 380,000 square feet of new facilities in Vacaville. Construction on the expansion began in the third quarter of 2004 and the new complex is expected to be licensed in the second half of 2009 with an investment of approximately $800 million.

Community Involvement Genentech's Vacaville facility is an established member of the Vacaville and Solano County communities. The company is a strong supporter of the local area through charitable donations to civic, cultural and educational non-profit organizations. In 2005, Genentech granted $500,000 to support construction of a new emergency room at VacaValley hospital to meet the needs of the local community.

Since 1993, Genentech has worked closely with local educational institutions to support and improve biotechnology education. Genentech and Solano Community College partnered to create an innovative workforce development model in the form of a biotechnology certificate program to provide technical education to students interested in careers in biotechnology. Genentech has also supported the University of California at Davis through frequent biotechnology lectures, research collaborations and student internships. In addition, each year, local students participate in the Genentech Scholars Program, a program for high school and college students that provides educational scholarships and gives college-level students the opportunity to augment their academic knowledge with "real-world" industry experience through an internship at Genentech.

Genentech employees are active in a wide array of community-based initiatives as volunteers and civic leaders. In addition, Genentech supports the local community through corporate contributions, volunteering and other outreach programs including the company's signature local economic development program, "Genentech Goes to Town," which provides Genentech employees "GenenMoney" to be used exclusively in Vacaville's downtown business district each fall. In 2008, the program celebrates its ninth year in Vacaville. Company-wide, since the "Genentech Goes to Town" was established, approximately $1.7 million has been distributed to support merchants in the company's hometowns.

About Genentech Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines for patients with significant unmet medical needs. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

September 2008